Sign In
Buy ADPT
$22.57
-1.61 (-6.66%)
At Close: Jul 31, 2026
Adaptive Biotechnologies Reports First Quarter 2025 Financial Results
04:05pm, Thursday, 01'st May 2025
SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gene
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025
04:05pm, Thursday, 10'th Apr 2025
SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune sys
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma
08:00am, Tuesday, 08'th Apr 2025
clonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remission clonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remiss
Enhanced assay granted approval by New York State's Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medica
Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the Upgrade
01:01pm, Wednesday, 12'th Feb 2025
Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
10:40am, Wednesday, 12'th Feb 2025
Here is how Adaptive Biotechnologies (ADPT) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.
Adaptive Biotechnologies Corporation (ADPT) Q4 2024 Earnings Call Transcript
07:47pm, Tuesday, 11'th Feb 2025
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q4 2024 Results Conference Call February 11, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of IR & FP&A Chad Robins - CEO and Co-Fou
Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
07:31pm, Tuesday, 11'th Feb 2025
The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates
06:36pm, Tuesday, 11'th Feb 2025
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.30 per share a year ago.
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results
04:05pm, Tuesday, 11'th Feb 2025
SEATTLE, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gen
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
04:05pm, Wednesday, 05'th Feb 2025
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gen
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
04:05pm, Wednesday, 22'nd Jan 2025
SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
10:41am, Friday, 17'th Jan 2025
Here is how Adaptive Biotechnologies (ADPT) and Bio-Rad Laboratories (BIO) have performed compared to their sector so far this year.
Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock?
09:35am, Thursday, 16'th Jan 2025
Adaptive Biotechnologies (ADPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stre
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
07:30am, Tuesday, 14'th Jan 2025
Pairing Adaptive Biotechnologies' clonoSEQ MRD results with NeoGenomics' COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum
